May. 12 at 2:40 PM
$EVAX Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress.
https://evaxion.ai/investors/press-releases/?press_release_id=11176
More great data coming. I have no doubt it’ll be amazing.
But no one gives a F. That’s the problem when you over promise and under deliver on partnerships year after year. NOW they are going to focus on partnerships. Well that’s what they said when they hired the former CEO a few years back and they still missed the ‘milestones’ every year. The difference now is they have stopped guiding revenue from deals.
Always frustrating when companies have great science and bad management.
I think it’s a big problem that MSD is a major shareholder. And the useless former CEO even bragged about how MSD stopped a deal with another partner to license EVX-B2 when the terms had been negotiated. Only to see MSD not exercise the option later. That drug could have been well underway.
